Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company headquartered in New York City, dedicated to developing and commercializing innovative treatments for B-cell malignancies and autoimmune diseases. The company has a rich pipeline of products aimed at addressing unmet medical needs in these areas.
One of TG Therapeutics' flagship products is BRIUMVI® (ublituximab-xiiy), a novel monoclonal antibody targeting CD20-expressing B-cells. BRIUMVI is FDA-approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company has also received approval from the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of RMS in Europe and the United Kingdom, respectively.
In addition to BRIUMVI, TG Therapeutics is advancing several other therapies:
- TG-1701 (BTK inhibitor)
- TG-1801 (anti-CD47/CD19 bispecific mAb)
Recent company news highlights the robust clinical activity of BRIUMVI, as demonstrated in the ULTIMATE I & II Phase 3 trials, and the company’s ongoing commitment to the multiple sclerosis community. TG Therapeutics has also been awarded a national contract with the Department of Veterans Affairs (VA) to list BRIUMVI as the preferred agent on the VA National Formulary for Anti-CD20 Antibody indications.
Financially, TG Therapeutics reported strong first-quarter 2024 sales, with BRIUMVI U.S. net revenue exceeding $50 million, leading to revised annual guidance of $270 to $290 million for 2024. The company is focused on expanding its commercial infrastructure and advancing its research pipeline, including developing a subcutaneous form of BRIUMVI and moving the therapy into additional indications beyond MS.
For more information, visit the company’s website at www.tgtherapeutics.com.
TG Therapeutics reported strong financial results for the first quarter of 2024 with BRIUMVI U.S. net revenue of $50.5 million, total revenue of $63.5 million, and updated yearly guidance to $270 to $290 million in BRIUMVI U.S. net revenue in 2024. The company is also making progress in clinical goals and advancing its pipeline. Recent highlights include the commercialization of BRIUMVI in the U.S. and Europe, obtaining additional patents, and entering into a global license agreement. Financially, the company saw significant growth in product revenue and net loss reduction.
TG Therapeutics, Inc. (NASDAQ: TGTX) will host a conference call on May 1, 2024, to discuss the first quarter financial results and the business outlook for 2024. The call will be led by Michael S. Weiss, Chairman and CEO. Participants can join via phone or webcast.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
What is TG Therapeutics' primary focus?
What is BRIUMVI?
Where is TG Therapeutics headquartered?
What recent financial performance did TG Therapeutics report?
Has BRIUMVI received regulatory approvals outside the U.S.?
What other therapies is TG Therapeutics developing?
What are the ULTIMATE I & II Phase 3 trials?
What support programs does TG Therapeutics offer for BRIUMVI?
What is the significance of TG Therapeutics' national contract with the VA?
Where can more information about TG Therapeutics be found?
